Medina JA, Correa R, Toledo MD. Estados iniciales del cáncer de cabeza y cuello. Papel de la radioterapia. Revisiones en Cancer 2010;24:16-24.
Corry J, Peters LJ, Rischin D. Impact of center size and experience on outcomes in head and neck cancer. J Clin Oncol 2015;33:138.
DOI: 10.1200/JCO.2014.58.2239
Beadle MD, Liao K, Elting L, Buchholz TA, Ang KK, Garden AS, et al. Improved survival using intensity-modulated radiation therapy in head and neck cancers: A SEER-Medicare analysis. Cancer 2014;120:702-10.
DOI: 10.1002/cncr.28372
Gómez-Millán J, Romero Fernández J, Medica Carmona JA. Current status of IMRT in head and neck cancer. Rep Pract Oncol Radiother 2013 Oct 20;18(6):371-5.
DOI: 10.1016/j.rpor.2013.09.008
Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006;116:1-13.
DOI: 10.1097/01.mlg.0000236095.97947.26
Tamura Y, Tanaka S, Asato R, Hirano S, Yamashita M, Tamaki H, et al. Therapeutic outcomes of laryngeal cancer at Kyoto University Hospital for10 years. Acta Otolaryngol Suppl 2007;127:62-6.
DOI: 10.1080/00016480601067990
Pfister D, Laurie S, Weinstein G, Mendenhall WM, Adelstein DJ, Ang KK, et al ; American Society of Clinical Oncology. American Society of Clinical practice guidelines for use of larynx- preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006;24(2):3693-704.
DOI: 10.1200/JCO.2006.07.4559
Vilaseca I, Huerta P, Blanch JL, Fernández-Planas AM, Jiménes C, Bernal-Sprekelse M, et al. Voice quality after CO2 laser cordectomy- what can we really expect? Head Neck 2008;30(1):43-9.
DOI: 10.1002/hed.20659
Mendenhall W, Werning J, Hinerman R, Amdur RJ, Villaret DB. Management of T1-T2 glottic carcinomas. Cancer 2004;100:1786-92.
DOI: 10.1002/cncr.20181
Groome PA, O´Sullivan B, Mackillop WJ, Jackson LD, Schulze K, Irish JC, et al. Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: Population-based outcomes study supporting need for intensified treatment schedules. Int J Radiat Oncol Biol Phys 2006;64(4):1002-12.
DOI: 10.1016/j.ijrobp.2005.10.010
Rutkowski T, Wygoda A, Skladowski K, et al. Predictors of radiotherapy outcome in patients with T2 supraglottic carcinoma. Eur Arch Otorhinolaryngol 2012 Mar; 269(3):923-9.
DOI: 10.1007/s00405-011-1847-9
Cabanillas R, Rodrigo JP, Llorente JL, Suárez C. Oncologic outcomes of transoral laser surgery of supraglottic carcinoma compared with a transcervical approach. Head Neck 2008;30(6):750-5.
DOI: 10.1002/hed.20778
Tamura Y, Tanaka S, Asato R, Hirano S, Yamashita M, Tamaki H, et al. Therapeutic outcomes of laryngeal cancer at Kyoto University Hospital for10 years. Acta Otolaryngol Suppl 2007;127:62-5.
DOI: 10.1080/00016480601067990
Lee N, Lu JJ. Target volume delineation and field setup. A practical guide for conformal and intensity modulated radiation therapy. Springer 2012.
DOI: 10.1007/978-3-642-28860-9
Mohamed ASR, Smith BD, Smith JB, Sevak P, Malek JS, Kanwar A, et al. Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. Laryngoscope. 2020;130(1):146-53.
DOI: 10.1002/lary.27873
Bicakci BC, Mustafayev TZ, Cetinayak O, Igem S, Birgi AD, Meydan D, et al. Outcomes of carotid sparing intensity-modulated radiotherapy for early stage glottic cancer in 201 patients: Multicenter study of Turkish Radiation Oncology Society/TROD-01-007. Head Neck 2022;44(8):1825.
DOI: 10.1002/hed.27101
Gujral DM, Long M, Roe J, Harrington KJ, Nutting CM. Standardisation of Target Volume Delineation for Carotid-sparing Intensity-modulated Radiotherapy in Early Glottis Cancer. Clin Oncol (R Coll Radiol) 2017:29(1):42-50.
DOI: 10.1016/j.clon.2016.09.017
Yamazaki H, Nishiyama K, Tananka E, Koizumi M, Chatani M. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 2006;64:77-82.
DOI: 10.1016/j.ijrobp.2005.06.014
Nutting M, Morden J, Harrington K, Guerrero Urbano T, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011;12:127-36.
DOI: 10.1016/S1470-2045(10)70290-4
Estimaciones de la incidencia del cáncer en España, 2022. Red Española de Registros de Cáncer (REDECAN); 2022.
D`Souza G, Gross N, Pai S, Haddad R, Anderson KS, Rajan S, et al. Oral Human Papillomavirus (HPV) Infection in HPV-Positive Patients with Oropharyngeal Cancer and Their Partners. J Clin Oncol 2014; 32(23):2408-15.
DOI: 10.1200/JCO.2014.55.1341
Gregoire V, Coche E, Cosnard G, Reychler H. Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience. Radiother Oncol 2000;56(2):135-50.
DOI: 10.1016/S0167-8140(00)00202-4
Mendenhall W, Morris C, Amdur R, Hinerman RW, Malyapa RS, Werning JW, et al. Definitive radiotherapy for tonsillar squamous cell carcinoma. Am J Clin Oncol 2006;29:290-7.
DOI: 10.1097/01.coc.0000209510.19360.f9
Genden E, Kotz T, Tong C, Smith C, Sikora AG, Teng MS, et al. Transoral robotic resection and reconstruction for head and neck cancer. Laryngoscope 2011;121:1668-74.
DOI: 10.1002/lary.21845
Weinstein G, Quon H, Newman H, Chalian JA, Malloy K, Lin A, et al. Transoral robotic surgery alone for oropharyngeal cancer: an analysis of local control. Arch Otolaryngol Head Neck Surg 2012;138:628-34.
DOI: 10.1001/archoto.2012.1166
Amin DR, Philips R, Bertoni DG, Mastrolonardo EV, Campbell DJ, et al. Differences in Functional and Survival Outcomes Between Patients Receiving Primary Surgery vs Chemoradiation Therapy for Treatment of T1-T2 Oropharyngeal Squamous Cell Carcinoma JAMA Otolaryngol Head Neck Surg 2023;149(11):980-6.
DOI: 10.1001/jamaoto.2023.1944
De Virgilio A, Costantino A, Mercante G, Pellini R, Ferreli F, Malvezzi L, et al. Transoral robotic surgery and intensity‑modulated radiotherapy in the treatment of the oropharyngeal carcinoma: a systematic review and meta‑analysis. Eur Arch Otorhinolaryngol 2021;278:1321-35.
DOI: 10.1007/s00405-020-06224-z
Machiels P, Leemans R, Golusinski W, Grau C, Licitra L, Gregoire V, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(11):1462-75.
DOI: 10.1016/j.annonc.2020.07.011
Burr AR, Harari PM, Ko HC, Bruce JY, Kimple RK, Witek WE. Reducing radiotherapy target volume expansion for patients with HPV-associated oropharyngeal cancer. Oral Oncol 2019;92:52-6.
DOI: 10.1016/j.oraloncology.2019.03.013
García-Anaya MJ, Segado-Guillot S, Cabrera-Rodríguez J, Toledo-Serrano MD, Medina-Carmona JA, Gómez-Millán J. Dose and volume de-escalation of radiotherapy in head and neck cancer. Crit Rev Oncol Hematol 2023 Jun;186:103994.
DOI: 10.1016/j.critrevonc.2023.103994
Lim Y, Koo B, Lee J, Lim J-Y, Choi EC. Distributions of cervical lymph node metastases in oropharyngeal carcinoma: therapeutic implications for the N0 neck. Laryngoscope 2006;116:1148-52.
DOI: 10.1097/01.mlg.0000217543.40027.1d
Baujat B, Bourhis J, Blanchard P, Overgaard J, Ang KK, Saunders M, et al. Hyperfracionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev 2010;8(12).
DOI: 10.1002/14651858.CD002026.pub2
Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;362:933-40.
DOI: 10.1016/S0140-6736(03)14361-9
Gregoire V, Coche E, Cosnard G, Reychler H. Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standarizing terminology and procedure based on the surgical experience. Radiother Oncol 2000;56(2):135-50.
DOI: 10.1016/S0167-8140(00)00202-4
De Visscher J, Grond A, Botke G, van der Waal I. Results of radiotherapy for squamous cell carcinoma of the vermilion border of the lower lip. A retrospective analysis of 108 patients. Radiother Oncol 1996;39:9-14.
DOI: 10.1016/0167-8140(96)01716-1
McCombe D, MacGill K, Ainslie J, Beresford J, Matthews J. Squamous cell carcinoma of the lip: a retrospective review of the Peter MacCallum Cancer Institute experience 1979-88. Aust N Z J Surg 2000;70:358-61.
DOI: 10.1046/j.1440-1622.2000.01827.x
Harma P, Sculler D, Baker S. Malignant lesions of the oral cavity. In: Cummings CC, Frederickson JM, Harker LA, et al. Editors. Otolaryngology Head and Neck Surgery. St. Louis: Mosby-Year Book; 1998.
Kurokawa H, Yamashita Y, Takeda S, Zhang M, Fukuyama H, Takahashi T. Risk factors for late cervical lymph node metastases in patients with stage I or II carcinoma of the tongue. Head Neck 2002;24:731.
DOI: 10.1002/hed.10130
Sresty NV, Ramanjappa T, Raju AK, Muralidhar KR, Sudarshan G. Acquisition of equal or better planning results with interstitial brachytherapy when compared with intensity-modulated radiotherapy in tongue cancers. Brachytherapy 2010;9:235-8.
DOI: 10.1016/j.brachy.2009.05.006
Shao Hui Huang, De Almeida JR, Watson E, Glogauer M, Xu W, Keshavarzi S, et al. Short-term and long-term unstimulated saliva flow following unilateral vs bilateral radiotherapy for oropharyngeal carcinoma. Head Neck 2021;43:456-66.
DOI: 10.1002/hed.26496
Newman JR, Connolly TM, Illing EA, Kilgore ML, Locher JL, Carroll WR. Survival trends in Hypopharyngeal cancer: A population-based review. Laryngoscope 2015 Mar;125(3):624-9.
DOI: 10.1002/lary.24915
Kuo P, Chen MM, Decker RH, Yarbrough WG, Judson BL. Hypopharyngeal cancer incidence, treatment, and survival: temporal trends in the United States. Laryngoscope 2014; 124(9):2064-9.
DOI: 10.1002/lary.24651
Longton E, Lawson G, Bihin B, Mathieu I, Hanin F-X, Deheneffe S, et al. Individualized Prophylactic Neck Irradiation in Patients with cN0 Head and Neck Cancer Based on Sentinel Lymph Node(s) Identification: Definitive Results of a Prospective Phase 1-2 Study. Int J Radiat Oncol Biol Phys 2020;107(4):652-61.
DOI: 10.1016/j.ijrobp.2020.03.021
Ho FC, Tham IW, Earnest A, lee KM, Lu JJ. Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: A meta-analysis of clinical evidence. BMC Cancer 2012;12(1):98.
DOI: 10.1186/1471-2407-12-98
Beadle BM, Liao K-P, Elting LS, Buchholz TA, Ang KK, Garden AS, et al. Improved survival using intensity-modulated radiation therapy in head and neck cancers: A SEER-Medicare analysis. Cancer 2014;120(5):702-10.
DOI: 10.1002/cncr.28372
Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, et al. Long-term outcomes of intensity modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol 2014;110(3):398-403.
DOI: 10.1016/j.radonc.2013.10.020
Chen QY, Wen YF, Guo L, Liu H, Huang P-Y, Mo H-Y, et al. Concurrent chemoradiotherapy vs radiotherapy alone in nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 2011;103:1761-70.
DOI: 10.1093/jnci/djr432
He X, Pan Z, Guo X, Ye M, Zhang Z, He S, et al. The pattern of relapse and survival of elective irradiation of the upper neck for stage N0 nasopharyngeal carcinoma. Radiat Oncol 2012;7(1):35.
DOI: 10.1186/1748-717X-7-35
Tang LL, Huang C L, Zhang N, Jiang W, Wu Y-S, Huang SH, et al. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol 2022;23(4):479-90.
DOI: 10.1016/S1470-2045(22)00058-4
Pow EHN, Kwong DLW, McMillan AS, Wong MCM, Sham JST, Leung LH, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int J Radiat Oncol 2006;66(4):981-91.
DOI: 10.1016/j.ijrobp.2006.06.013
Peng G, Wang T, Yang K, Zhang S, Zhang T, Li Q, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 2012;104(3):286-93.
DOI: 10.1016/j.radonc.2012.08.013
Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27(22):3684.
DOI: 10.1200/JCO.2008.19.9109
Mazeron JJ, Ardiet JM, Haie-Méder C, Kovács G, Levendag P, Peiffert D, et al. GEC ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol 2009;91(2):150-6.
DOI: 10.1016/j.radonc.2009.01.005
Guinot JL, Arribas L, Vendrell JB, et al. Prognostic factors in squamous cell lip carcinoma treated with high-dose-rate brachytherapy. Head Neck 2014;36(12):1737-42.
DOI: 10.1002/hed.23529
Guinot JL, Arribas L, Vendrell JB, et al. Prognostic factors in squamous cell lip carcinoma treated with high-dose-rate brachytherapy. Head Neck 2014;36(12):1737-42.
DOI: 10.1002/hed.23529